Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York. Show more

Location: One World Trade Center, Suite 8500, New York, NY, 10007, United States | Website: https://www.mindmed.co | Industry: Biotechnology | Sector: Healthcare

Market Cap

689.4M

52 Wk Range

$4.70 - $11.02

Previous Close

$9.06

Open

$9.08

Volume

1,011,381

Day Range

$8.70 - $9.25

Enterprise Value

547.6M

Cash

183M

Avg Qtr Burn

-25.39M

Insider Ownership

0.84%

Institutional Own.

55.68%

Qtr Updated

06/30/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
MM120 (lysergide D-tartrate) Details Major depressive disorder	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MM120 (lysergide D-tartrate) Details Anxiety Disorders	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MM402 (R(-)-MDMA) Details Autism spectrum disorders	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.